These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 1057009)
1. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro. Furner RL; Mellett LB; Herren TC J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009 [TBL] [Abstract][Full Text] [Related]
2. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors. Kreis W; Hession C; Soricelli A; Scully K Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601 [TBL] [Abstract][Full Text] [Related]
3. Kinase and deaminase activity in a variety of subcutaneous mouse tumors. Furner RL; Mellett LB Cancer Res; 1975 Jul; 35(7):1799-803. PubMed ID: 165884 [TBL] [Abstract][Full Text] [Related]
4. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice. Avramis VI; Powell W Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332 [TBL] [Abstract][Full Text] [Related]
5. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells. White JC; Hines LH Cancer Res; 1987 Apr; 47(7):1820-4. PubMed ID: 3028615 [TBL] [Abstract][Full Text] [Related]
6. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755. Boothman DA; Briggle TV; Greer S Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761 [TBL] [Abstract][Full Text] [Related]
7. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013 [TBL] [Abstract][Full Text] [Related]
8. Cellular phosphorylation of 1-beta-D-arabinofuranosylcytosine 5-azacytidine with intact fibrosarcoma and leukemic cells. Lee T; Karon M; Monparler RL Cancer Res; 1975 Sep; 35(9):2506-10. PubMed ID: 50132 [TBL] [Abstract][Full Text] [Related]
9. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies. Mekras JA; Boothman DA; Greer SB Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216 [TBL] [Abstract][Full Text] [Related]
10. Correlation of mouse tissue distribution of arabinosylcytosine in vivo with enzymatic activities in vitro. Ho DH Drug Metab Dispos; 1976; 4(3):296-300. PubMed ID: 6236 [TBL] [Abstract][Full Text] [Related]
11. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412 [TBL] [Abstract][Full Text] [Related]
12. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies. Mekras JA; Boothman DA; Perez LM; Greer S Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164 [TBL] [Abstract][Full Text] [Related]
13. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice. Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678 [TBL] [Abstract][Full Text] [Related]
14. A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells. White JC; Capizzi RL Cancer Res; 1991 May; 51(10):2559-65. PubMed ID: 2021937 [TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Bhalla K; Nayak R; Grant S Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869 [TBL] [Abstract][Full Text] [Related]
16. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells. Wan CW; Mak TW Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637 [TBL] [Abstract][Full Text] [Related]
17. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells. Walsh CT; Craig RW; Agarwal RP Cancer Res; 1980 Sep; 40(9):3286-92. PubMed ID: 7427943 [TBL] [Abstract][Full Text] [Related]
18. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man. Kreis W; Woodcock TM; Gordon CS; Krakoff IH Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600 [TBL] [Abstract][Full Text] [Related]
19. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Brockman RW; Cheng YC; Schabel FM; Montgomery JA Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636 [TBL] [Abstract][Full Text] [Related]
20. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid. Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]